Leukemia

The FDA has approved enasidenib (Idhifa) for the treatment of relapsed or refractory IDH2-mutant acute myeloid leukemia.

Dose optimization of nilotinib is feasible and may help patients with chronic-phase chronic myeloid leukemia achieve molecular responses, according to results of a new study.

A large genomic sequencing analysis of patients with T-ALL revealed a new landscape of mutations that may inform future treatment strategies.

Treatment with imatinib results in good overall survival in patients with chronic myeloid leukemia, approaching a normal life expectancy, according to the CML-IV study.

The FDA has granted priority review status for two new indications of dasatinib (Sprycel), according to the drug’s developer.

Researchers have identified two distinct stem cell–like populations from which relapse can arise in AML patients, which may help clinicians identify who will and won't respond to standard chemotherapy.

Treatment of adult relapsed or refractory acute lymphoblastic leukemia with inotuzumab ozogamicin was associated with increased hepatotoxicity, especially after follow-up hematopoietic stem cell transplantation.

The FDA has expanded the approval of blinatumomab (Blincyto) for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia in adults and children.

ODAC approval of Novartis' CAR T-Cell therapy paves the way for its FDA approval as a commercially available treatment for B-cell ALL.

There was no significant survival difference in newly diagnosed acute myeloid leukemia patients given induction therapy with idarubicin vs high-dose daunorubicin.

A new study in JCO suggests that genetic variations within AML patients with CD33 may predict their response to gemtuzumab ozogamicin.

Approximately half of patients with chronic-phase CML who achieved a sustained deep molecular response with nilotinib were able to discontinue therapy and remain in treatment-free remission through 96 weeks.

A follow-up analysis of the CheckMate-205 clinical trial found that nivolumab was associated with durable response rates in adults with relapsed or refractory Hodgkin lymphoma after ASCT.

This video reviews the biology of secondary acute myeloid leukemia and highlights some of the latest findings in the treatment of this disease.

Adult patients with early thymic precursor (ETP) acute lymphoblastic leukemia (ALL), a subgroup of T-cell ALL, could benefit from the use of response-based risk stratification and therapy intensification similar to that used in pediatric patients with ETP-ALL.

Adding the novel CD20 inhibitor ublituximab to ibrutinib offered improved response rates and greater depth of response over ibrutinib alone in patients with relapsed/refractory chronic lymphocytic leukemia.

Adding midostaurin to chemotherapy prolonged survival in younger adult patients with acute myeloid leukemia and a FLT3 mutation, according to a randomized trial.

A de-escalation of tyrosine-kinase inhibitor dose was safe in the majority of patients with chronic myeloid leukemia with stable major molecular response.

Lenalidomide plus rituximab induction therapy followed by maintenance appears to provide favorable activity and a tolerable safety profile in follicular lymphoma patients who are double-refractory or had early relapse after initial diagnosis.

Over recent years, there has been much progress in elucidating the biology of these lymphomas, and this has paved the way for novel therapies that are currently under investigation in clinical trials.

Anti-CD19 CAR T-cell therapy may benefit patients with aggressive B-cell non-Hodgkin lymphoma who have relapsed or are refractory to standard therapy.

This video examines the targeting of IDH1/IDH2 mutations in patients with relapsed or refractory acute myeloid leukemia.

Dasatinib was safe and effective in pediatric patients with chronic myeloid leukemia, according to a new study, establishing the agent as a new standard of care for this population.

The novel IDH2-inhibitor enasidenib was well tolerated and offered durable responses in a phase I trial of relapsed or refractory acute myeloid leukemia patients with an IDH2 mutation.

Brentuximab vedotin, a monoclonal antibody-drug conjugate, combined with gemcitabine may be a new treatment option for children and AYAs with relapsed or refractory Hodgkin lymphoma.

Despite immune-related adverse events, concurrent ibrutinib and anti-CD19 CAR T-cell therapy may improve response rates in patients with chronic lymphocytic leukemia.

A fifth course of cytarabine chemotherapy resulted in improved overall and disease-free survival in pediatric patients with low-risk acute myeloid leukemia.

Researchers are making much-needed progress in developing treatments for patients with three rare malignancies: recurrent and refractory primary central nervous (CNS) system lymphoma, secondary CNS lymphoma, and primary vitreoretinal lymphoma.

Chromosomal abnormalities such as a variant t(9;22) translocation do not appear to have significant prognostic impact on children with chronic myeloid leukemia.